GlassScriptPhysician profile
Ryan S Morris
NPI 1558746362
$9,096.22
in general payments reported to CMS, 2019-2025
16 companies · $1,080 in 2025
The $1,080 reported for 2025 was more than what 82% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7,387 · 2022: $306 · 2023: $155 · 2024: $168 · 2025: $1,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,294 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,293.83 |
| Education | $109.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,723.68 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $646.70 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $601.53 | 2025 | Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $486.05 | 2021-2022 | |
| Alkermes, INC. | $354.01 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $307.15 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $273.54 | 2022-2023 | Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $161.23 | 2021 | |
| Sunovion Pharmaceuticals INC. | $119.98 | 2021 | |
| Eisai INC. | $110.34 | 2021 | |
| Lundbeck LLC | $81.29 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $75.34 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $74.25 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52.97 | 2022 | |
| Allergan, INC. | $14.25 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $13.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.